[1] Hallsworth K, Adams LA. Lifestyle modification in NAFLD/NASH: Facts and figures. JHEP reports,2019,1:468-479.
[2] Rinella ME. Nonalcoholic fatty liver disease: a systematic review. JAMA,2015,313:2263-2273.
[3] Liss KH, Finck BN. PPARs and nonalcoholic fatty liver disease. Biochimie, 2017,136:65-74.
[4] Rohit A Sinha?,Sangam Rajak,Brijesh K Singh. et al.Hepatic Lipid Catabolism via PPARα-Lysosomal Crosstalk.Int J Mol Sci,2020,21:E2391.
[5] Cave MC, Clair HB, Hardesty JE.et al. Nuclear receptors and nonalcoholic fatty liver disease. Biochim Biophys Acta,2016,1859:1083-1099.
[6] Bodzin AS1, Busuttil RW1. Hepatocellular carcinoma: Advances in diagnosis, management, and long term outcome. World J Hepatol,2015,7:1157-67.
[7] Kersten S, Stienstra R.The role and regulation of the peroxisome proliferator activated receptor alpha in human liver. Biochimie,2017,136:75-84.
[8] Han L, Shen WJ, Bittner S. et al. PPARs: regulators of metabolism and as therapeutic targets in cardiovascular disease. Part I: PPAR-α.Future Cardiol,2017,13:259-278.
[9] Stec DE, Gordon DM, Hipp JA. et al. Loss of hepatic PPARα promotes inflammation and serum hyperlipidemia in diet-induced obesity. Am J Physiol Regul Integr Comp Physiol, 2019,317:733-745.
[10] Li G, Brocker CN, Xie C.et al. Hepatic peroxisome proliferator-activated receptor alpha mediates the major metabolic effects of Wy-14643. J Gastroenterol Hepatol, 2018,33:1138-1145.
[11] Wahli W, Michalik L. PPARs at the crossroads of lipid signaling and inflammation. Trends Endocrinol Metab, 2012, 23:351-363.
[12] Pettinelli P, Videla LA. Up-regulation of PPAR-gamma mRNA expression in the liver of obese patients: an additional reinforcing lipogenic mechanism to SREBP-1c induction. J Clin Endocrinol Metab, 2011,96:1424-1430.
[13] Schroeder F, McIntosh AL, Martin GG.et al.Fatty Acid Binding Protein-1 (FABP1) and the Human FABP1 T94A Variant: Roles in the Endocannabinoid System and Dyslipidemias. Lipids, 2016,51:655-76.
[14] Pawlak M, Lefebvre P, Staels B.et al. Molecular mechanism of PPARalpha action and its impact on lipid metabolism, inflammation and fibrosis in non-alcoholic fatty liver disease. J Hepatol,2015,62:720–733.
[15] Zhang N, Lu Y, Shen X.et al. Fenofibrate treatment attenuated chronic endoplasmic reticulum stress in the liver of nonalcoholic fatty liver disease mice. Pharmacology, 2015, 95:173-180.
[16] Ke Y, Xu C, Lin J. et al.Role of Hepatokines in Non-alcoholic Fatty Liver Disease. J Transl Intern Med,2019,7:143-148.
[17] Pan X, Schwartz GJ, Hussain MM. et al.Oleoylethanolamide differentially regulates glycerolipid synthesis and lipoprotein secretion in intestine and liver. J Lipid Res,2018,59:2349-2359.
[18] Hafiane A, Gasbarrino K, Daskalopoulou SS. The role of adiponectin in cholesterol efflux and HDL biogenesis and metabolism. Metabolism,2019,100:153953-153964.
[19] Samuel VT, Shulman GI.Nonalcoholic Fatty Liver Disease as a Nexus of Metabolic and Hepatic Diseases. Cell Metab. 2018,27:22-41.
[20] Ke Y, Xu C, Lin J. et al.Role of Hepatokines in Non-alcoholic Fatty Liver Disease.J Transl Int Med, 2019,7:143-148.
[21] Piccinin E, Moschetta A.Hepatic-specific PPARα-FGF21 action in NAFLD.Gut,2016,65:1075-1076.
[22] Camporez JP, Jornayvaz FR, Petersen MC. et al. Cellular mechanisms by which FGF21 improves insulin sensitivity in male mice. Endocrinology, 2013,154:3099-3109.
[23] Madureira TV, Pinheiro I, Malh?o F.et al.Silencing of PPARαBb mRNA in brown trout primary hepatocytes: effects on molecular and morphological targets under the influence of an estrogen and a PPARα agonist.Comp Biochem Physiol B Biochem Mol Biol, 2019,229:1-9.
[24] Huang J, Jia Y, Fu T. et al.Sustained activation of PPARα by endogenous ligands increases hepatic fatty acid oxidation and prevents obesity in ob/ob mice.FASEB J,2012,26:628-638.
[25] Yu G, Cheng CJ, Lin SC. et al.Organelle-Derived Acetyl-CoA Promotes Prostate Cancer Cell Survival, Migration, and Metastasis via Activation of Calmodulin Kinase II.Cancer Res,2018, 78:2490-2502.
[26] Lebeaupin C, Vallée D, Hazari Y.et al.Endoplasmic reticulum stress signalling and the pathogenesis of non-alcoholic fatty liver disease.J Hepatol, 2018,69:927-947.
[27] Chen X,Zhang F,Gong Q.et al.Hepatic ATF6 Increases Fatty Acid Oxidation to Attenuate Hepatic Steatosis in Mice Through Peroxisome Proliferator-Activated Receptor α. Diabetes,2016,65:1904-1915.
[28] Jao TM, Nangaku M, Wu CH. et al.ATF6α downregulation of PPARα promotes lipotoxicity-induced tubulointerstitial fibrosis. Kidney Int,2019,95:577-589. |
